The administration of Punica fraction was given orally using a stomach tube. The results demonstrated that the administration Punica fraction 50, 100, and 200 mg/kg BW significantly prevented bone loss in OVX rats which these effect equivalent to Tamoxifen. These effects were described in increased mineral content of calcium. On histology data shown that fraction could increased osteoblast number.
CONDUCTED BY: Faculty of Pharmacy, University of Indonesia
PUBLISHED ON: International Journal of Herbal Medicine
The effects of Polar fraction of Punica granatum peel extract on bone loss in ovariectomized (ovx) rats model of osteoporosis were investigated. Forty two 6 weeks old female Sprague–Dawley rats were randomly assigned to seven groups as followed, sham-operated, OVX, OVX-Estradiol (0.5 mg/kgBW), OVXTamoxifen (50 mg/kg BW), OVX-Punica fraction (PF) 50 mg/kg BW, OVX-PF 100 mg/kg BW and OVXPF 200 mg/kg BW for 4 weeks.
The administration of Punica fraction was given orally using a stomach tube. The results demonstrated that the administration Punica fraction 50, 100, and 200 mg/kg BW significantly prevented bone loss in OVX rats which these effect equivalent to Tamoxifen. These effects were described in increased mineral content of calcium. On histology data shown that fraction could increased osteoblast number. This result indicated that polar fraction of ethanolic extract of pomegranate have potential as a drug for osteoporosis.
The aims of this work were to investigate the effects of the pomegranate fraction on bone protection and effects on reproductive organs. Ovariectomized rats are classically used as an animal model for studying the effect of postmenopausal bone loss. Furthermore, they may provide a useful model for investigating the biological effect of PF on bone loss in ovariectomized rats. Pomegranate Fraction from polar part of Punica granatum (L) extract contain tannins especially Ellagic acid [115, 16].
Previous study shown that ellagic acid prevent bone loss by increasing mineralization of bone through osteoblast. And others studies shows ellagic acid has no effect on epithelial cell of uterus and antiestrogenic on MCF7 cell lines. The present study was investigated the potential preventive effects of tannin-content pomegranate fraction of Punica granatum L. which contain ellagic acid to prevent bone loss in animal model of osteoporosis.
The administration of PF prevented OVX-induced increase average body weight gain in rats. This results also support by previous study that compound that prevented OVX-induced uterine atrophy and increases in body weight gain, abdominal fat, serum total cholesterol and triglyceride. In addition, other study also reported that soybeans-rich isoflavones dietary interventions effectively reduce cholesterol serum in OVX-induced increased cholesterol serum in rats. According with previous report, rats in the OVX group had lower densities of the right femur and tibiae because of reducing the ovariectomy-induced increase in bone resorption.
The administration of Pomegranate fraction 50, 100 and 200 mg/kg BB effectively prevented OVX-induced lowering bone density. These observations are supported by previous study that ellagic acid significantly prevented bone loss in OVX rats by increasing mineralization of bone. Further studies are needed to investigate the efficacy of that ellagic acid in humans.